| APAM |
Artisan Partners Asset Management Inc. |
72%
|
er for the RA Fund and may be deemed a beneficial owner of ADSs held by the RA Fund. The RA Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities hel… |
| APAM |
Artisan Partners Asset Management Inc. |
72%
|
Reciprocal relationship from APAM graph: Reciprocal relationship from ASND graph: er for the RA Fund and may be deemed a beneficial owner of ADSs held by the RA Fund. The RA Fund has delegated to RA … |
| HOWL |
Werewolf Therapeutics, Inc. |
72%
|
Reciprocal relationship from HOWL graph: lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a… |
| JHG |
Janus Henderson Group plc |
72%
|
rizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the consolidated statements of financial position: (EUR’000) < 1 year 1-5 years >5 years Tota… |
| JHG |
Janus Henderson Group plc |
72%
|
Reciprocal relationship from JHG graph: Reciprocal relationship from ASND graph: rizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the consolid… |
| NKTR |
Nektar Therapeutics |
72%
|
roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and reports; and returned or salvaged products… |
| NKTR |
Nektar Therapeutics |
72%
|
Reciprocal relationship from NKTR graph: Reciprocal relationship from ASND graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from ASND graph: Reciprocal relationship from NKTR g… |
| NVO |
Novo Nordisk A/S |
72%
|
established an integrated organization to commercialize the Company’s approved Endocrinology Rare Disease products, YORVIPATH ® and SKYTROFA ® . In Europe, the Company has established its presence by… |
| NVO |
Novo Nordisk A/S |
72%
|
Reciprocal relationship from NVO graph: Reciprocal relationship from ASND graph: Reciprocal relationship from NVO graph: Reciprocal relationship from ASND graph: established an integrated organizatio… |
| OPK |
OPKO Health, Inc. |
72%
|
roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and reports; and returned or salvaged products… |
| OPK |
OPKO Health, Inc. |
72%
|
Reciprocal relationship from OPK graph: aboratories, molecular diagnostic firms, universities and research institutions. Most of these companies have substantially greater financial and other resourc… |
| SER |
Serina Therapeutics, Inc. |
72%
|
roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and reports; and returned or salvaged products… |
| SER |
Serina Therapeutics, Inc. |
72%
|
Reciprocal relationship from SER graph: Reciprocal relationship from ASND graph: Reciprocal relationship from SER graph: Reciprocal relationship from ASND graph: Reciprocal relationship from SER grap… |
| SNYNF |
Sanofi |
72%
|
LPs”), for certain nonclinical studies, and good clinical practices (“GCPs”), for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA and comparable foreign regulatory … |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ASND graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ASND graph: Reciprocal relationship from SNYN… |
| AVORO-CAPITAL-ADVISORS-LLC |
AVORO-CAPITAL-ADVISORS-LLC |
62%
|
er for the RA Fund and may be deemed a beneficial owner of ADSs held by the RA Fund. The RA Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities hel… |
| BACHEM-AG |
BACHEM-AG |
62%
|
roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and reports; and returned or salvaged products… |
| CARBOGEN-AMCIS-AG |
CARBOGEN-AMCIS-AG |
62%
|
rly Medicom Innovation Partner A/S). The intermediates of our proprietary TransCon linkers are made by CARBOGEN AMCIS AG under an agreement with CARBOGEN AMCIS AG and accompanying purchase orders. Fo… |
| EXTEND-BIOSCIENCES-NEKTAR-THERAPEUTICS-OPKO-HEAL |
EXTEND-BIOSCIENCES-NEKTAR-THERAPEUTICS-OPKO-HEAL |
62%
|
roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and reports; and returned or salvaged products… |
| FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-UK-LIMITED |
FUJIFILM-DIOSYNTH-BIOTECHNOLOGIES-UK-LIMITED |
62%
|
th Fujifilm Diosynth Biotechnologies UK Limited (“Fujifilm”), and Lonza Ltd. Our PTH as well as our TransCon PTH drug substance is supplied by Bachem, Switzerland, pursuant to our agreement with Bach… |
| GENESCIENCE-PHARMACEUTICALS-CO-LTD |
GENESCIENCE-PHARMACEUTICALS-CO-LTD |
62%
|
LPs”), for certain nonclinical studies, and good clinical practices (“GCPs”), for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA and comparable foreign regulatory … |
| NOF-CORPORATION |
NOF-CORPORATION |
62%
|
rly Medicom Innovation Partner A/S). The intermediates of our proprietary TransCon linkers are made by CARBOGEN AMCIS AG under an agreement with CARBOGEN AMCIS AG and accompanying purchase orders. Fo… |
| OPKO-HEALTH-INC |
OPKO-HEALTH-INC |
62%
|
LPs”), for certain nonclinical studies, and good clinical practices (“GCPs”), for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA and comparable foreign regulatory … |
| RA-CAPITAL-MANAGEMENT-GP-LLC |
RA-CAPITAL-MANAGEMENT-GP-LLC |
62%
|
general partner of the RA Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the controlling persons. RA Capital serves as investm… |
| VETTER-PHARMA-INTERNATIONAL-GMBH |
VETTER-PHARMA-INTERNATIONAL-GMBH |
62%
|
roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and reports; and returned or salvaged products… |
| WESTFIELD-CAPITAL-MANAGEMENT-COMPANY |
WESTFIELD-CAPITAL-MANAGEMENT-COMPANY |
62%
|
er for the RA Fund and may be deemed a beneficial owner of ADSs held by the RA Fund. The RA Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities hel… |
| YPSOMED-AG |
YPSOMED-AG |
62%
|
ges and assembles the cartridges with a drug delivery device made by Ypsomed AG. CNP drug substance is supplied by Wacker Biotech, Germany. Our TransCon CNP drug product in vials is manufactured by V… |
